Rolling BLA submission for nomlabofusp has begun, with FDA alignment on the data package and FXN as a surrogate endpoint. Open label study data show sustained FXN increases and clinical improvements at 1 year and 18 months, with a favorable safety profile. Global Phase 3 trial is set to start dosing in Q3 2026.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.